Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II …

Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro‐inflammatory and anti‐inflammatory mediator production …

Background Apremilast works intracellularly to regulate inflammatory mediators. Objective
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …

Psoriasis is a chronic, systemic, inflammatory disease with manifestations resulting from a
dysregulated immune response. In psoriatic skin, expression of all phosphodiesterase 4 …

Introduction: Psoriasis is a chronic inflammatory skin disease characterized by erythematous
plaques on extensor surfaces, scalp, and back. Current therapies for psoriasis are limited by …

Apremilast, an oral, small‐molecule phosphodiesterase 4 inhibitor, works intracellularly
within immune cells to regulate inflammatory mediators. This phase 2b randomized, placebo …

Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …

Objective: To evaluate the clinical and biological activity of apremilast in patients with severe
plaque-type psoriasis. Research design and methods: Apremilast, a phosphodiesterase‑4 …

Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …

BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …